DelveInsight’s, “Cancer Vaccines Competitive landscape 2025” report provides comprehensive insights about 250+ companies and 300+ drugs in Cancer Vaccines Competitive landscape. It covers the Cancer Vaccines therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the full insights into the evolving Cancer Vaccines Pipeline and discover which companies are leading the innovation race @ Cancer Vaccines Competitive Landscape Report
Key Takeaways from the Cancer Vaccines Pipeline Report
- On 24 August 2025, Columbia University announced a study of the 9vHPV vaccine among a population of children, adolescents, and young women living with HIV in Eswatini. This protocol seeks to assess immunogenicity of a two-dose 9vHPV vaccine regimen among girls and boys (9-14 years) and young women (15-26 years) living with HIV on antiretroviral therapy versus a three-dose 9vHPV vaccine regimen among HIV uninfected young women (15-26 years) in Eswatini.
- DelveInsight’s Cancer Vaccines competitive landscape report depicts a robust space with 250+ active players working to develop 300+ pipeline therapies for Cancer Vaccines treatment.
- The leading Cancer Vaccines Companies such as Imvax, Transgene, BrightPath Biotherapeutics, Vaccitech, Amal Therapeutics, Enterome, Moderna, Inc., Ultimovacs ASA OSE Immunotherapeutic, IO Biotech, PDS Biotech, LIKANGLIFE SCIENCES, ISA Pharmaceuticals Voltron Therapeutics, Inc., RNAImmune, and others.
- Promising Cancer Vaccines Therapies such as GX-188E, ACIT-1, V503, VGX 3100, GSK 1437173A, Gardasil ® 9, Cervarix™, RV001V, CDX-1401, 9vHPV Vaccine, Pembrolizumab and others.
Unlock detailed analysis of the Cancer Vaccines Competitive Landscape 2025 and identify key growth opportunities @ Cancer Vaccines Research and Development Report
Cancer Vaccines Marketed Therapies
- Dendreon Corporation
Dendreon is a biotechnology company. Its lead product, Provenge (known generically as sipuleucel-T), is an immunotherapy for prostate cancer. It consists of a mixture of the patient’s own blood cells (autologous, with dendritic cells thought to be the most important) that have been incubated with the Dendreon PAP-GM-CSF fusion protein. Dendreon’s name derives from the “”Dendritic Cell”” which forms a major component of the company’s product candidates that use the “”Dendreon Cassette Technology”” to insert a disease-specific target protein into a general platform. Dendreon believes its process can be optimized and generalized to other diseases by exchanging the PAP component of Provenge with better targets specific to different diseased cells.
- Provenge
Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared specifically for each patient. In metastatic prostate cancer, it has extended survival by median 4.1 months (IMPACT Phase III trial data). Sipuleucel-T is marketed under the brand name Provenge by Dendreon Corporation. Sipuleucel-T was approved by the US Food and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic Metastatic Hormone-Refractory Prostate Cancer (HRPC).
- Merck & Co., Inc.
Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of its mission to save and improve lives. The company continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – and aspires to be the premier research-intensive biopharmaceutical company in the world.
- H101
HPV) Types 16, 18, 31, 33, 45, 52, and 58; cervical, vulvar, and anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11. While it is indicated in males 9 through 45 years of age for the prevention of anal, oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58; anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11.
Cancer Vaccines Pipeline Therapies and Company
- OSE Immunotherapeutics
OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. The company’s immunology research and development platform is focused on three areas: T-cell-based vaccination, Immuno-Oncology (focus on myeloid targets), Auto-immunity & Inflammation. Its balanced first-in-class clinical and preclinical portfolio has a diversified risk profile. Tedopi (innovative combination of neoepitopes) is the the company’s most advanced product.
- Tedopi
Tedopi (formerly known as OSE-2101), is a cancer vaccine being developed by OSE Immunotherapeutics for the treatment of certain types of lung cancer. It contains a combination of 10 optimized neo-epitopes, which are parts of proteins that structurally alter cancer cells and trigger strong immune responses against them. The epitopes present in Tedopi are optimized from five tumorous antigens. The epitopes express a minimum of one of the tumor antigens and generate a specific response from cytotoxic (aka killer) T-cells against cancer cells. Tedopi works by stimulating killer T-cells, enabling them to spot and eliminate cancerous cells, which is a key process in the treatment of disease. Tedopi has been granted orphan drug designation by the US Food and Drug Administration (FDA) and is recognized as a personalized medicine for the treatment of HLA-A2 positive NSCLC patients in Europe.
- IO Biotech
IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform. The T-win® platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. IO Biotech is advancing in clinical studies its lead immuno-oncology candidate, IO102-IO103, targeting IDO and PD-L1, and through clinical and preclinical development its other pipeline candidates. IO Biotech is headquartered in Copenhagen, Denmark.
- IO102-IO103
IO102-IO103 is an investigational cancer immunotherapy designed to target the immunosuppressive mechanisms mediated by the key immunosuppressive proteins indoleamine 2,3-dehydrogenase (IDO) and PD-L1. The combination is currently investigated in Phase III trial for Melanoma and in Phase I/II for some other cancers. IO102 and IO103 are IO Biotech’s lead immuno-oncology candidates. Both compounds are based on IO Biotech’s proprietary T-win® technology platform which enables the identification of compounds with a dual mechanism of action targeting and directly killing immunosuppressive cells and tumor cells while indirectly activating other T-effectors, leading to strong anti-tumor responses without adding additional safety concern. Specifically, IO102 and IO103 are first-in-class, immune modulatory vaccines designed to engage and activate IDO and PD-L1 specific human T-cells.
- PDS Biotech
PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology platform. Versamune® effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them.
- PDS0101
PDS0101 is a novel investigational human papilloma virus (HPV)-targeted immunotherapy that stimulates a potent targeted T cell attack against HPV-positive cancers. PDS0101 is given by a simple subcutaneous injection in combination with other immunotherapies and cancer treatments. Interim data suggests PDS0101 generates clinically effective immune responses, and the combination of PDS0101 with other treatments demonstrates significant disease control by shrinking tumors, delaying disease progression and/or prolonging survival. The combination of PDS0101 with other treatments does not appear to compound the toxicity of other agents. PDS0101 is currently being evaluated in four Phase 2 clinical trials for the treatment of various types of HPV-positive cancers.
Gain strategic intelligence on Cancer Vaccines Emerging Therapies, pipeline highlights, and competitive trends shaping the Cancer Vaccines market @ Cancer Vaccines Preclinical and Discovery Stage Products
Cancer Vaccines Analytical Perspective by DelveInsight
In-depth Commercial Assessment: Cancer Vaccines Collaboration Analysis by Companies
The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.
Cancer Vaccines Competitive Landscape
The report comprises of comparative assessment of Companies (by therapy, development stage, and technology).
Cancer Vaccines Competitive Landscape Report Assessment
- Cancer Vaccines Company Analysis
- Cancer Vaccines Therapeutic Assessment
- Cancer Vaccines Pipeline Assessment
- Cancer Vaccines Inactive drugs assessment
- Cancer Vaccines Unmet Needs
Stay informed on the latest advancements in Cancer Vaccines research and development—Download the in-depth pipeline and competitive landscape report @ Cancer Vaccines Market Drivers and Barriers
Scope of the Cancer Vaccines Market Report
- Coverage- Global
- Cancer Vaccines Companies- Imvax, Transgene, BrightPath Biotherapeutics, Vaccitech, Amal Therapeutics, Enterome, Moderna, Inc., Ultimovacs ASA OSE Immunotherapeutic, IO Biotech, PDS Biotech, LIKANGLIFE SCIENCES, ISA Pharmaceuticals Voltron Therapeutics, Inc., RNAImmune, and others.
- Cancer Vaccines Therapies- GX-188E, ACIT-1, V503, VGX 3100, GSK 1437173A, Gardasil ® 9, Cervarix™, RV001V, CDX-1401, 9vHPV Vaccine, Pembrolizumab and others.
- Cancer Vaccines Marketed Therapies and Pipeline Therapies
- Cancer Vaccines Preclinical and Discovery Stage Products, Unmet Needs
Understand the Cancer Vaccines Companies, drugs, and market dynamics driving the Cancer Vaccines Pipeline in 2025—Request your copy of the report now @ Cancer Vaccines Mechanism of Action and Unmet Needs
Table of Contents
- Introduction
- Executive Summary
- Cancer Vaccines: Overview
- Cancer Vaccines -Analytical Perspective: In-depth Commercial Assessment
- Competitive Landscape
- Therapeutic Assessment
- Cancer Vaccines: Company and Product Profiles (Marketed Therapies)
- Dendreon Corporation
- Provenge
- Cancer Vaccines: Company and Product Profiles (Pipeline Therapies)
- Late Stage Products (Phase III)
- OSE Immunotherapeutics
- Tedopi
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Company Name
- Product Name
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Company Name
- Drug Name
- Preclinical and Discovery Stage Products
- Company Name
- Product Name
- Inactive Products
- Cancer Vaccines- Unmet needs
- Cancer Vaccines – Market drivers and barriers
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/cancer-vaccines-competitive-landscape